Axogen, Inc.

# Signal Note: Perceptive Advisors Initiates AXGN Position Perceptive's $25.7M entry into Axogen—a nerve repair biotech with an established commercial portfolio (Avance, Axoguard)—suggests conviction in upcoming catalysts, likely the FDA decision on its flagship Avance nerve allograft in critical indications or margin expansion from recent M&A integrations. Edelman's clinical-stage track record implies he's positioning ahead of near-term data readouts or regulatory milestones that could validate the company's regenerative medicine platform beyond its current surgical revenue base.